FASN and ovarian cancer: For ovarian cancer, aberrant activation of FASN oncogenic pathway cause the compromised antitumor immune response by lipid accumulation in tumor-infiltrating dendritic cells and then T-cells exclusion and dysfunction (71); and its inhibitors TVB3664 could be combined with other drugs for enhancing treatment efficacy of HCC (72).